Editor's note - Page 7 of 13 - Express Pharma

Dull Q4FY17 could be a blessing in disguise

Towards sustainability

Bridging the skills gap

Passing the buck?

Does IP build or block?

US-India relationship: Can it trump the odds?

Collaborate to conquer

Evolving an ‘India First’ policy

Beyond the budget

Pharma PSUs: Missed opportunity?